Merck KGaA (MRK) Receives Average Recommendation of “Hold” from Brokerages

Merck KGaA (FRA:MRK) has been given an average rating of “Hold” by the twenty-one ratings firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is €98.74 ($114.81).

Several analysts have recently commented on MRK shares. Commerzbank set a €100.00 ($116.28) target price on Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, November 14th. Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA and gave the company a “buy” rating in a research note on Tuesday, November 13th. Kepler Capital Markets set a €108.00 ($125.58) target price on Merck KGaA and gave the company a “buy” rating in a research note on Thursday, November 15th. Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the company a “buy” rating in a research note on Thursday, November 15th. Finally, Berenberg Bank set a €102.00 ($118.60) target price on Merck KGaA and gave the company a “buy” rating in a research note on Friday, November 23rd.

Get Merck KGaA alerts:

Shares of MRK traded up €1.76 ($2.05) during trading hours on Friday, hitting €92.54 ($107.60). The stock had a trading volume of 721,278 shares. Merck KGaA has a 1-year low of €76.60 ($89.07) and a 1-year high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: Compound Interest and Why It Matters When Investing